Cargando…

Simian adenoviruses as vaccine vectors

Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morris, Susan J, Sebastian, Sarah, Spencer, Alexandra J, Gilbert, Sarah C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842362/ https://www.ncbi.nlm.nih.gov/pubmed/29527232 http://dx.doi.org/10.2217/fvl-2016-0070

Ejemplares similares

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
por: O’Hara, Geraldine A., et al.
Publicado: (2012)

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
por: Gilbert, Sarah C., et al.
Publicado: (2017)

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens
por: Antrobus, Richard D, et al.
Publicado: (2014)

Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines
por: Lan, Wendong, et al.
Publicado: (2023)

Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
por: Rollier, Christine S., et al.
Publicado: (2020)

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
por: Fedosyuk, Sofiya, et al.
Publicado: (2019)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults
por: Coughlan, L., et al.
Publicado: (2018)

Adenoviruses as vaccine vectors
por: Tatsis, Nia, et al.
Publicado: (2004)

A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017)

A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis
por: Wang, Chuan, et al.
Publicado: (2018)

Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
por: Ewer, Katie, et al.
Publicado: (2017)

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
por: Dicks, Matthew D. J., et al.
Publicado: (2012)

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
por: Folegatti, Pedro M, et al.
Publicado: (2022)

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
por: Warimwe, George M, et al.
Publicado: (2013)

A high infectious simian adenovirus type 23 vector based vaccine efficiently protects common marmosets against Zika virus infection
por: Luo, Shengxue, et al.
Publicado: (2020)

Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
por: Munster, Vincent J., et al.
Publicado: (2017)

Simian adenoviruses: Molecular and serological survey in monkeys and humans in Thailand
por: Kosoltanapiwat, Nathamon, et al.
Publicado: (2022)

Cytokine Responses to Adenovirus and Adenovirus Vectors
por: Atasheva, Svetlana, et al.
Publicado: (2022)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2017)

Adenovirus Vectors: Excellent Tools for Vaccine Development
por: Chang, Jun
Publicado: (2021)

Adenovirus vector-based vaccine for infectious diseases
por: Sakurai, Fuminori, et al.
Publicado: (2022)

Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate
por: Petherbridge, Lawrence, et al.
Publicado: (2023)

Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
por: Koger-Pease, Cal, et al.
Publicado: (2023)

Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus
por: Vitelli, Alessandra, et al.
Publicado: (2013)

COVID-19 Vaccines Based on Adenovirus Vectors
por: Hasanpourghadi, Mohadeseh, et al.
Publicado: (2021)

First evidence of a new simian adenovirus clustering with Human mastadenovirusF viruses
por: Lange, Christian E., et al.
Publicado: (2019)

Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2023)

Isolation of a novel monkey adenovirus reveals a new phylogenetic clade in the evolutionary history of simian adenoviruses
por: Maluquer de Motes, Carlos, et al.
Publicado: (2011)

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
por: Jenkin, Daniel, et al.
Publicado: (2022)

Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]
por: Coughlan, L., et al.
Publicado: (2018)

Development of nonhuman adenoviruses as vaccine vectors
por: Bangari, Dinesh S., et al.
Publicado: (2006)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

P17-20. Lentiviral vector-based vaccine against SIV infection and simian AIDS
por: Beignon, A, et al.
Publicado: (2009)

Identification of New Provisional Simian Adenovirus Species from Captive Monkeys, China
por: Foytich, Kimberly R., et al.
Publicado: (2014)

Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer
por: Cappuccini, Federica, et al.
Publicado: (2016)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method
por: Roy, Chad J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p671flj2bvf1m5mqk1samupp3a